Surrozen reports FY2024 net loss of $63.6M; secures $76.4M financing for ophthalmology pipeline

Surrozen, Inc./DE

2025-Q1 EPS reported -$7.43 vs consensus -$1.82 ▼ miss (-308.1%)

Net loss $63.6M for 2024 vs $43.0M in 2023; Q4 net loss $28.0M.
Cash $34.6M at 12/31/2024; received $76.4M gross proceeds from March 2025 financing.
Collaboration revenue $10.0M for 2024, driven by Boehringer milestone; zero in 2023.
R&D expenses $21.1M, down from $27.2M in 2023 due to restructuring and program discontinuation.
Company prioritizing ophthalmology programs; Boehringer advancing SZN-413 toward clinical testing.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.